Spyre Therapeutics, Inc.SYRENASDAQ
Loading
EBITDA Over TimeContracting
Percentile Rank9
Studio
Year-over-Year Change

Earnings before interest, taxes, depreciation, and amortization

Latest
$-179.22M
↓ 96% vs avg
Percentile
P9
Near historical low
Streak
1 yr
Consecutive growthContracting
Average
$-91.27M
Historical baseline
PeriodValueYoY Change
TTM$-179.22M+13.8%
2024$-207.97M-63.0%
2023$-127.60M-54.1%
2022$-82.82M-29.3%
2021$-64.07M+19.2%
2020$-79.27M-2.5%
2019$-77.35M-71.2%
2018$-45.17M-64.7%
2017$-27.43M-26.0%
2016$-21.77M-